Clinician's guide to hepatitis C

Mayo Clinic Proceedings

Volumn 73, Issue 4, 1998, Pages 355-361

  Gross Jr , John B ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE TRANSMISSION; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; OCCUPATIONAL HAZARD; REVIEW; RISK ASSESSMENT; SEXUAL INTERCOURSE; VERTICAL TRANSMISSION;

EID: 0031894449     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-6196(11)63702-6     Document Type: Review

References (12)

1. Management of hepatitis C [Consensus Conference]. Hepatology 1997;26(Suppl 1):1S-155S
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al (Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team). The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905
3. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14
4. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (Collaborative Study Group). Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to Interferon therapy. Ann Intern Med 1996;125:634-639
5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C (OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups). Lancet 1997;349:825-832
6. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472
7. Gross JB Jr, Persing DH. Hepatitis C: advances in diagnosis. Mayo Clin Proc 1995;70:296-297
8. Yano M, Yatsuhashi H, Inoue 0, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 1993;34(Suppl 2):S13-S16
9. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356
10. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of Interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-789
11. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-874
12. Centers for Disease Control. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Morb Mortal Wkly Rep 1991;40(Suppl RR-4):1-17